Bioinformatics Senior Scientist – Orion, Turku26.5.2019
Orion Corporation is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients.
Description of position
As a member of the newly established Biologics and New modalities Discovery Groups you will work closely with cross-functional teams to provide computational biology support to the antibody and new modalities discovery process. Your primary responsibilities will include the application of structural analysis to sequences from both internal and public databases to enable therapeutic protein design, oligonucleotide designs, gene editing designs, CRISPR-based gene editing, and antibody repertoire analysis.
The identification of relevant liabilities in nucleotide sequences will be a critical responsibility in order to successfully support generation and optimization of the modalities (therapeutic oligonucleotide, peptides and biologics). You support day to day laboratory work in-house and you will therefore have a good possibility to do a lot of hands-on laboratory work verifying the computational designs. You will be also the primary contact with collaborations with partners and CROs on your expertise areas. You will be based in Turku.
Exciting opportunities to create and have an impact to the future therapies for patients.
In Orion we have a highly interesting R&D pipeline and enthusiastic working environment with opportunities to use your own strengths to build your competence development and career. As an expert of your own field you will be a member of multi-disciplinary team jointly innovating and developing new treatments for the patients. Appreciation of colleagues and continuous development are part of our core values. The culture of Orion R&D is informal and we enjoy working together.
We are passionate about the patient welfare and serve as The Voice of Science and the Patient – if this inspires you too – join us!
Description of the unit
Orion’s pharmaceutical innovations are created within its R&D organization, including e.g. non-clinical research, clinical development, formulation development and medical affairs. The organization employs top professionals in the field of drug molecule development and optimization.
The newly established Biologics and New Modalities team is part of our R&D organization and it is responsible for bringing as new treatment modalities for Orion’s pipeline covering therapeutic nucleotides, delivery technologies and gene therapy. Adding the possibility to modulate the target with either small or large molecules enables us to choose the right target and then use the best modalities to modulate the target protein in order to create the best value for patients. To fulfill this exciting task the New Modalities function is strengthened by recruiting new R&D experts with a track record of on advanced therapy modalities. The function is currently to set up and you have a great opportunity to be part of developing our processes.
To operate successfully in this position you should have a PhD degree in genetics, molecular biology, computational or biology structural biology with several years of post-doctoral experience in computational biology to support optimization of therapeutic large molecules. You should also have thorough understanding of in vitro models for system biology and biophysical data analysis.
Willingness to create new things is a must because you will join a team that is just recently set up. The role includes collaboration within Orion and with various collaborators, therefore strong communication skills and an ability to convince your audience is an asset.
Would you like to know more about the position? Please contact Jyrki Lehtimäki, Senior Manager, Strategic Development, +358509667478. He is best available during the following times (Finnish times): 17th and 24th May 15.00-17.00 pm. Please send your application latest on 2 June 2019.